Published in Cancer Law Weekly, October 2nd, 2004
Compounds covered by the new patent include methods for treating cancer using Vascular Targeting Agents (VTAs) that bind to tumor blood vessels combined with standard cancer therapies including radiotherapy and chemotherapy.
These novel VTA compounds may be directed to targets included in Peregrine's Anti- Phospholipid Therapy (APT) platform to enhance the anti-tumor effects of standard anticancer therapies without harming normal, healthy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.